S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.55
+1.87
+11.21%
MRNA · Moderna, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
$245.94
+3.65
(+1.51%)
● At close: October 21 at 4:00:00 PM EDT
$241.08
-4.73
(-1.92%)
Pre-Market:
5:13:33 AM EDT
DAY'S RANGE
$245.94
$240.19
$254.43
52-WEEK RANGE
$245.94
$22.28
$243.98
What's happening
- MRNA is up 1.51% today, trading at $245.94. — Live quote
- It's trading within 3% of its 52-week high ($243.98). (Finnhub fundamentals)
- Volume today (446,513) is well below its 3-month average of 16,496,330. (Finnhub fundamentals)
- Reports earnings on 2026-11-06 (before market open), 15 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.97 actual vs. $-2.12 estimated (+7.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 7
Hold 16
Sell 3
Strong sell 1
Aggregate ratings for 2026-10-01 (31 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
MRNA
+720.89%
vs S&P 500
+708.11%
1-YEAR RETURN
MRNA
+788.69%
vs S&P 500
+774.13%
6-MONTH RETURN
MRNA
+342.72%
3-MONTH RETURN
MRNA
+305.77%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.97
Est. $-2.12
BEAT +7.3%
2026-04-26 (Q1 2026)
$-3.40
Est. $-4.04
BEAT +15.8%
2026-01-26 (Q4 2025)
$-2.11
Est. $-2.70
BEAT +21.7%
2025-10-26 (Q3 2025)
$-0.51
Est. $-2.15
BEAT +76.3%
Valuation Measures & Ratios
Enterprise Value4$95.53B
Forward P/E5—
PEG Ratio6-4.58
Price / Sales (TTM1)43.37
Price / Book74.11
EV4 / Revenue42.88
EV4 / EBITDA109.05
Profit Margin-141.43%
Operating Margin-149.01%
Return on Equity (ROE8)-39.20%
Return on Assets (ROA9)-26.86%
Avg Volume (3M)16,496,330
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $27.79B | $20.07B | $10.12B | $10.68B | $10.92B |
| P/E | -8.82 | -6.01 | -5.10 | -3.49 | -3.20 |
| Price/Sales | 16.42 | 12.13 | 3.24 | 4.54 | 4.59 |
| Price/Book | 4.11 | 2.71 | 1.08 | 1.14 | 1.08 |
| EV/Revenue | 15.75 | 11.33 | 2.87 | 3.99 | 3.91 |
| EV/EBITDA | -8.46 | -5.51 | -4.30 | — | — |
| ROE | -46.59% | -45.07% | -21.25% | -32.58% | -33.90% |
| ROA | -28.74% | -29.07% | -16.34% | -25.50% | -26.86% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Analyst Insights
Source: Financial Modeling Prep analyst consensus (price targets + ratings). Not a recommendation — see balanced evidence below for sourced strengths and concerns instead.
Short Interest
Shares Short30,863,202
Change from Prior Settlement-6.11%
% of Float8.30%
Days to Cover (Short Ratio)1.83
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 2.1% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +788.7%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -141.4%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MRNA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $145.0M | $389.0M | $1.02B | $142.0M | $108.0M | $1.86B | $241.0M | $167.0M |
| Operating income | -$815.0M | -$1.39B | -$260.0M | -$907.0M | -$1.05B | -$70.0M | -$1.36B | -$1.27B |
| Net income | -$782.0M | -$1.34B | -$200.0M | -$825.0M | -$971.0M | $13.0M | -$1.28B | -$1.18B |
| EPS (diluted) | $-1.97 | $-3.40 | $-0.51 | $-2.13 | $-2.52 | $0.03 | $-3.33 | $-3.07 |
| EPS (basic) | $-1.97 | $-3.40 | $-0.51 | $-2.13 | $-2.52 | $0.03 | $-3.33 | $-3.07 |
| Operating margin | -$562 | -$357 | -$26 | -$639 | -$972 | -$4 | -$566 | -$758 |
| Net margin | -$539 | -$345 | -$20 | -$581 | -$899 | $1 | -$531 | -$704 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $10.96B | $11.49B | $12.34B | $12.13B | $12.01B | $12.70B | $14.14B | $15.80B |
| Total liabilities | $4.20B | $4.08B | $3.69B | $2.81B | $2.61B | $2.64B | $3.24B | $3.88B |
| Stockholders' equity | $6.76B | $7.41B | $8.65B | $9.33B | $9.40B | $10.07B | $10.90B | $11.93B |
| Total current assets | $5.82B | $5.77B | $6.54B | $6.60B | $6.17B | $6.77B | $8.10B | $9.67B |
| Total current liabilities | $2.53B | $2.40B | $1.99B | $1.68B | $1.57B | $1.60B | $2.21B | $2.20B |
| Cash & equivalents | $1.72B | $1.91B | $2.60B | $1.13B | $1.28B | $1.62B | $1.93B | $1.64B |
| Accounts receivable | $17.0M | $71.0M | $184.0M | $1.05B | $36.0M | $78.0M | $358.0M | $1.56B |
| Inventory | $280.0M | $146.0M | $153.0M | $332.0M | $240.0M | $128.0M | $117.0M | $412.0M |
| Other current assets | $42.0M | $51.0M | $45.0M | $56.0M | $57.0M | $69.0M | $58.0M | $46.0M |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | $52.0M | $52.0M | $52.0M | $52.0M | $52.0M | $52.0M | $52.0M | $52.0M |
| Intangible assets | $109.0M | $116.0M | $45.0M | $47.0M | $48.0M | $49.0M | $40.0M | $41.0M |
| Other non-current assets | $618.0M | $675.0M | $605.0M | $530.0M | $546.0M | $556.0M | $594.0M | $556.0M |
| Accounts payable | $167.0M | $161.0M | $317.0M | $267.0M | $175.0M | $226.0M | $405.0M | $373.0M |
| Accrued liabilities | $1.91B | $1.91B | $1.39B | $1.18B | $987.0M | $1.00B | $1.43B | $1.38B |
| Deferred revenue (current) | $295.0M | $102.0M | $99.0M | $163.0M | $218.0M | $125.0M | $153.0M | $379.0M |
| Other current liabilities | $163.0M | $220.0M | $185.0M | $73.0M | $192.0M | $252.0M | $221.0M | $69.0M |
| Long-term debt | $591.0M | $590.0M | $590.0M | — | — | — | $0 | — |
| Other non-current liabilities | $284.0M | $283.0M | $285.0M | $281.0M | $276.0M | $274.0M | $267.0M | $276.0M |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | $5.10B | $5.88B | $7.22B | $8.05B | $8.25B | $9.07B | $10.04B | $11.16B |
| Accumulated other comprehensive income (loss) | $19.0M | $25.0M | $45.0M | $27.0M | $23.0M | $10.0M | -$10.0M | $11.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$526.0M | -$630.0M | $930.0M | -$847.0M | -$919.0M | -$1.04B | $825.0M | -$1.57B |
| Investing cash flow | $329.0M | -$76.0M | -$48.0M | $700.0M | $564.0M | $730.0M | -$539.0M | $721.0M |
| Financing cash flow | $14.0M | $17.0M | $581.0M | -$1.0M | $9.0M | $4.0M | -$3.0M | $11.0M |
| Free cash flow | -$563.0M | -$692.0M | $891.0M | -$880.0M | -$922.0M | -$1.15B | $303.0M | -$1.72B |
| Capital expenditures | $37.0M | $62.0M | $39.0M | $33.0M | $3.0M | $117.0M | $522.0M | $151.0M |
| Depreciation & amortization | $56.0M | $56.0M | $173.0M | $51.0M | $56.0M | $38.0M | $150.0M | $51.0M |
| Share-based compensation | $120.0M | $104.0M | $113.0M | $125.0M | $130.0M | $115.0M | $104.0M | $112.0M |
| Deferred income taxes | — | — | $10.0M | — | — | — | -$1.0M | — |
| Change in accounts receivable | -$53.0M | -$114.0M | -$859.0M | $1.01B | -$30.0M | -$280.0M | -$1.21B | $1.40B |
| Change in inventory | $132.0M | -$6.0M | -$179.0M | $91.0M | $114.0M | $8.0M | -$291.0M | $11.0M |
| Change in accounts payable | -$8.0M | -$120.0M | $22.0M | $89.0M | -$47.0M | -$156.0M | $34.0M | $96.0M |
| Purchases of investments | $556.0M | $1.35B | $1.55B | $1.16B | $1.29B | $1.76B | $1.89B | $1.25B |
| Sales/maturities of investments | $212.0M | $602.0M | $609.0M | $685.0M | $371.0M | $688.0M | $957.0M | $1.01B |
| Share repurchases | — | — | $2.0M | — | — | — | $0 | $0 |
| Tax withholding on stock comp | $2.0M | $2.0M | — | $0 | $0 | $1.0M | — | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B |
| Operating income | -$3.07B | -$3.94B | -$4.24B | $9.42B | $13.30B |
| Net income | -$2.82B | -$3.56B | -$4.71B | $8.36B | $12.20B |
| EPS (diluted) | $-7.26 | $-9.28 | $-12.33 | $20.12 | $28.29 |
| EPS (basic) | $-7.26 | $-9.28 | $-12.33 | $21.26 | $30.31 |
| Operating margin | -$158 | -$122 | -$62 | $49 | $72 |
| Net margin | -$145 | -$110 | -$69 | $43 | $66 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $12.34B | $14.14B | $18.43B | $25.86B | $24.67B |
| Total liabilities | $3.69B | $3.24B | $4.57B | $6.74B | $10.52B |
| Stockholders' equity | $8.65B | $10.90B | $13.85B | $19.12B | $14.14B |
| Total current assets | $6.54B | $8.10B | $10.32B | $13.43B | $16.07B |
| Total current liabilities | $1.99B | $2.21B | $3.02B | $4.92B | $9.13B |
| Cash & equivalents | $2.60B | $1.93B | $2.91B | $3.21B | $6.85B |
| Accounts receivable | $184.0M | $358.0M | $892.0M | $1.39B | $3.17B |
| Inventory | $153.0M | $117.0M | $202.0M | $949.0M | $1.44B |
| Other current assets | $45.0M | $58.0M | $88.0M | $44.0M | $26.0M |
| Property, plant & equipment | — | — | — | — | — |
| Goodwill | $52.0M | $52.0M | $52.0M | $0 | — |
| Intangible assets | $45.0M | $40.0M | $44.0M | $0 | — |
| Other non-current assets | $605.0M | $594.0M | $766.0M | $988.0M | $46.0M |
| Accounts payable | $317.0M | $405.0M | $520.0M | $487.0M | $302.0M |
| Accrued liabilities | $1.39B | $1.43B | $1.80B | $2.10B | $1.47B |
| Deferred revenue (current) | $99.0M | $153.0M | $568.0M | $2.04B | $6.25B |
| Other current liabilities | $185.0M | $221.0M | $129.0M | $249.0M | $225.0M |
| Long-term debt | $590.0M | $0 | — | — | — |
| Other non-current liabilities | $285.0M | $267.0M | $256.0M | $135.0M | $76.0M |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | $7.22B | $10.04B | $13.61B | $18.32B | $9.96B |
| Accumulated other comprehensive income (loss) | $45.0M | -$10.0M | -$123.0M | -$370.0M | -$24.0M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$1.87B | -$3.00B | -$3.12B | $4.98B | $13.62B |
| Investing cash flow | $1.95B | $1.95B | $4.21B | -$5.18B | -$8.52B |
| Financing cash flow | $593.0M | $56.0M | -$1.38B | -$3.45B | -$873.0M |
| Free cash flow | -$2.06B | -$4.05B | -$3.83B | $4.58B | $13.34B |
| Capital expenditures | $192.0M | $1.05B | $707.0M | $400.0M | $284.0M |
| Depreciation & amortization | $211.0M | $185.0M | $617.0M | $348.0M | $232.0M |
| Share-based compensation | $483.0M | $429.0M | $305.0M | $226.0M | $142.0M |
| Deferred income taxes | $10.0M | -$1.0M | $901.0M | -$578.0M | -$296.0M |
| Change in accounts receivable | -$156.0M | -$534.0M | -$493.0M | -$1.79B | $1.78B |
| Change in inventory | $34.0M | -$83.0M | -$747.0M | -$492.0M | $1.39B |
| Change in accounts payable | -$92.0M | -$69.0M | $13.0M | $240.0M | $204.0M |
| Purchases of investments | $5.77B | $6.53B | $3.76B | $11.44B | $12.65B |
| Sales/maturities of investments | $2.35B | $3.97B | $3.21B | $3.55B | $3.10B |
| Share repurchases | $2.0M | $0 | $1.15B | $3.33B | $857.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MRNA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers68.5%
Shares Outstanding399,000,000
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| FMR LLC | 51,859,891 | $3.63B | 13.00% | +13.5% | 2026-08-13 |
| BlackRock, Inc. | 30,599,409 | $2.14B | 7.67% | +3.3% | 2026-08-07 |
| VANGUARD CAPITAL MANAGEMENT LLC | 23,208,792 | $1.63B | 5.82% | +1.5% | 2026-06-30 |
| Capital World Investors | 22,276,996 | $1.56B | 5.58% | +19.1% | 2026-08-07 |
| BAILLIE GIFFORD & CO | 18,206,778 | $1.28B | 4.56% | -8.9% | 2026-08-06 |
| State Street Corp | 15,726,193 | $1.10B | 3.94% | +5.8% | 2026-08-07 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 15,581,313 | $1.09B | 3.91% | -0.2% | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 9,710,335 | $678.8M | 2.43% | +2.9% | 2026-08-12 |
| Morgan Stanley | 9,538,094 | $668.0M | 2.39% | +12.6% | 2026-08-11 |
| Theleme Partners LLP | 8,057,571 | $564.3M | 2.02% | +0.1% | 2026-08-13 |
| TWO SIGMA INVESTMENTS, LP | 7,193,530 | $503.8M | 1.80% | -20.8% | 2026-08-07 |
| Invesco Ltd. | 5,780,299 | $404.8M | 1.45% | +20.8% | 2026-08-13 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5,589,560 | $391.4K | 1.40% | +656.8% | 2026-08-14 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4,838,884 | $338.9M | 1.21% | +2.2% | 2026-08-14 |
| Goldman Sachs Group Inc | 4,671,950 | $327.2M | 1.17% | -29.3% | 2026-08-14 |
| Flagship Pioneering, LLC | 4,632,149 | $324.4M | 1.16% | +0.0% | 2026-08-14 |
| UBS Group AG | 4,463,211 | $312.6M | 1.12% | +1.3% | 2026-08-13 |
| BNP PARIBAS FINANCIAL MARKETS | 4,377,120 | $306.5M | 1.10% | +1.4% | 2026-08-10 |
| NORGES BANK | 3,026,074 | $211.9M | 0.76% | +0.0% | 2026-08-12 |
| Northern Trust Corp | 2,985,329 | $209.1M | 0.75% | +1.1% | 2026-08-12 |
| BANQUE PICTET & CIE SA | 2,699,402 | $189.0M | 0.68% | -1.8% | 2026-07-14 |
| DIMENSIONAL FUND ADVISORS LP | 2,468,775 | $172.9M | 0.62% | +15.8% | 2026-08-11 |
| WELLINGTON MANAGEMENT GROUP LLP | 2,461,574 | $172.4M | 0.62% | +4.4% | 2026-08-14 |
| Merck & Co., Inc. | 2,308,190 | $161.6M | 0.58% | +0.0% | 2026-08-07 |
| Citigroup Inc | 2,165,414 | $151.6M | 0.54% | +46.3% | 2026-08-03 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-05-27 to 2026-10-15
Recent transactions
- Insiders have net sold 806,640 shares over the last 182 days, across 0 purchases and 15 sales.
- Most recent: Hoge Stephen (President) — Option exercise of 76,452 shares on 2026-10-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)806,640 sh(15 txns)
Net Shares-806,640
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Hoge Stephen | President | Option exercise | 2026-10-15 | 76,452 |
| Mock James M | Chief Financial Officer | Option exercise | 2026-10-05 | 1,454 |
| Klinger Shannon Thyme | Chief Legal Officer | Option exercise | 2026-09-04 | 11,797 |
| Bancel Stephane | Chief Executive Officer | Option exercise | 2026-08-06 | 252,469 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-15 | Hoge Stephen | President | Option exercise | 76,452 | $12.21 |
| 2026-10-15 | Hoge Stephen | President | Open market sale | 39,145 | $220.72 |
| 2026-10-14 | Hoge Stephen | President | Option exercise | 76,453 | $12.21 |
| 2026-10-14 | Hoge Stephen | President | Open market sale | 38,774 | $213.47 |
| 2026-10-14 | Hoge Stephen | President | Open market sale | 450 | $214.15 |
| 2026-10-05 | Mock James M | Chief Financial Officer | Option exercise | 1,454 | — |
| 2026-10-05 | Mock James M | Chief Financial Officer | Tax withholding | 704 | $190.01 |
| 2026-09-15 | Hoge Stephen | President | Option exercise | 76,452 | $12.21 |
| 2026-09-15 | Hoge Stephen | President | Open market sale | 40,281 | $146.07 |
| 2026-09-14 | Hoge Stephen | President | Option exercise | 76,453 | $12.21 |
| 2026-09-14 | Hoge Stephen | President | Open market sale | 40,294 | $144.13 |
| 2026-09-10 | Mock James M | Chief Financial Officer | Option exercise | 19,836 | $30.96 |
| 2026-09-10 | Mock James M | Chief Financial Officer | Open market sale | 19,836 | $134.49 |
| 2026-09-10 | Mock James M | Chief Financial Officer | Open market sale | 15,000 | $134.49 |
| 2026-09-04 | Mock James M | Chief Financial Officer | Option exercise | 11,797 | — |
| 2026-09-04 | Mock James M | Chief Financial Officer | Tax withholding | 5,704 | $148.87 |
| 2026-09-04 | Klinger Shannon Thyme | Chief Legal Officer | Option exercise | 11,797 | — |
| 2026-09-04 | Klinger Shannon Thyme | Chief Legal Officer | Tax withholding | 5,704 | $148.87 |
| 2026-09-01 | Klinger Shannon Thyme | Chief Legal Officer | Option exercise | 3,471 | $30.96 |
| 2026-09-01 | Klinger Shannon Thyme | Chief Legal Officer | Open market sale | 3,471 | $139.95 |
| 2026-09-01 | Klinger Shannon Thyme | Chief Legal Officer | Option exercise | 2,166 | — |
| 2026-09-01 | Klinger Shannon Thyme | Chief Legal Officer | Tax withholding | 1,048 | $140.34 |
| 2026-09-01 | Mock James M | Chief Financial Officer | Option exercise | 2,475 | — |
| 2026-09-01 | Mock James M | Chief Financial Officer | Tax withholding | 1,197 | $140.34 |
| 2026-09-01 | Hoge Stephen | President | Option exercise | 9,283 | — |
| 2026-09-01 | Hoge Stephen | President | Tax withholding | 4,489 | $140.34 |
| 2026-08-28 | Hoge Stephen | President | Option exercise | 611 | — |
| 2026-08-28 | Hoge Stephen | President | Tax withholding | 296 | $142.77 |
| 2026-08-28 | Klinger Shannon Thyme | Chief Legal Officer | Option exercise | 329 | — |
| 2026-08-28 | Klinger Shannon Thyme | Chief Legal Officer | Tax withholding | 160 | $142.77 |
| 2026-08-28 | Mock James M | Chief Financial Officer | Option exercise | 329 | — |
| 2026-08-28 | Mock James M | Chief Financial Officer | Tax withholding | 160 | $142.77 |
| 2026-08-27 | Hoge Stephen | President | Option exercise | 1,437 | — |
| 2026-08-27 | Hoge Stephen | President | Tax withholding | 695 | $149.66 |
| 2026-08-27 | Klinger Shannon Thyme | Chief Legal Officer | Option exercise | 774 | — |
| 2026-08-27 | Klinger Shannon Thyme | Chief Legal Officer | Tax withholding | 375 | $149.66 |
| 2026-08-27 | Mock James M | Chief Financial Officer | Option exercise | 774 | — |
| 2026-08-27 | Mock James M | Chief Financial Officer | Tax withholding | 375 | $149.66 |
| 2026-08-06 | Bancel Stephane | Chief Executive Officer | Option exercise | 252,469 | $19.15 |
| 2026-08-05 | Bancel Stephane | Chief Executive Officer | Option exercise | 499,246 | $19.15 |
| 2026-08-05 | Bancel Stephane | Chief Executive Officer | Open market sale | 147,473 | $56.21 |
| 2026-08-05 | Bancel Stephane | Chief Executive Officer | Open market sale | 124,838 | $56.96 |
| 2026-08-05 | Bancel Stephane | Chief Executive Officer | Open market sale | 39,891 | $58.12 |
| 2026-08-05 | Bancel Stephane | Chief Executive Officer | Open market sale | 187,044 | $58.79 |
| 2026-07-15 | Hoge Stephen | President | Option exercise | 37,226 | $19.15 |
| 2026-07-15 | Hoge Stephen | President | Option exercise | 16,110 | $19.15 |
| 2026-07-15 | Hoge Stephen | President | Open market sale | 53,336 | $67.60 |
| 2026-07-02 | Mock James M | Chief Financial Officer | Option exercise | 1,452 | — |
| 2026-07-02 | Mock James M | Chief Financial Officer | Tax withholding | 703 | $72.50 |
| 2026-06-15 | Hoge Stephen | President | Option exercise | 37,226 | $19.15 |
| 2026-06-15 | Hoge Stephen | President | Option exercise | 16,110 | $19.15 |
| 2026-06-15 | Hoge Stephen | President | Open market sale | 53,336 | $51.37 |
| 2026-06-05 | Klinger Shannon Thyme | Chief Legal Officer | Option exercise | 11,798 | — |
| 2026-06-05 | Klinger Shannon Thyme | Chief Legal Officer | Tax withholding | 5,705 | $51.59 |
| 2026-06-05 | Mock James M | Chief Financial Officer | Option exercise | 11,798 | — |
| 2026-06-05 | Mock James M | Chief Financial Officer | Tax withholding | 5,705 | $51.59 |
| 2026-06-04 | Klinger Shannon Thyme | Chief Legal Officer | Option exercise | 3,471 | $30.96 |
| 2026-06-04 | Klinger Shannon Thyme | Chief Legal Officer | Open market sale | 3,471 | $50.00 |
| 2026-06-01 | Mock James M | Chief Financial Officer | Option exercise | 2,475 | — |
| 2026-06-01 | Mock James M | Chief Financial Officer | Tax withholding | 1,197 | $47.19 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:14 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 4 | 2026-10-14 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-09-30 | 8-K | 2026-09-30 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-01 | 8-K | 2026-08-27 | View on SEC.gov → |
| 2026-08-31 | 4 | 2026-08-27 | View on SEC.gov → |
Recent news
Headlines about MRNA (Moderna, Inc.). Links open the publisher — we don’t host full articles.
-
Is Moderna (MRNA) Fully Valued Following Its NASDAQ 100 Inclusion?
Yahoo Finance · 2026-10-22 -
MRNA Jan 2027 160.000 call (MRNA270115C00160000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-22 -
Why Did MRNA, CVX, V Stocks Jump To 52-Week Highs Today?
Yahoo Finance · 2026-10-22 -
MRNA Nov 2026 300.000 call (MRNA261113C00300000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-22 -
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
Stocktwits · 2026-10-22 -
MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading
Stocktwits · 2026-10-22 -
MRNA Oct 2026 305.000 put (MRNA261030P00305000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
MRNA Oct 2026 305.000 put (MRNA261030P00305000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21
No headlines in this category right now — try “All”.